Trade Report: Today, Gilead Sciences Inc. (GILD) Stake Raised by Simmons Bank

Today, Gilead Sciences Inc. (GILD) Stake Raised by Simmons Bank

Simmons Bank boosted its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 2.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,855 shares of the biopharmaceutical company’s stock after buying an additional 650 shares during the period. Simmons Bank’s holdings in Gilead Sciences were worth $1,887,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Van Hulzen Asset Management LLC increased its position in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Gemmer Asset Management LLC increased its position in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Joel Isaacson & Co. LLC increased its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Roble Belko & Company Inc increased its position in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the period. Finally, Pinkerton Retirement Specialists LLC increased its position in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the period. 73.59% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% on Monday, reaching $74.54. The company’s stock had a trading volume of 9,338,882 shares. The firm has a market cap of $98.20 billion, a PE ratio of 6.89 and a beta of 1.25. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $107.38. The stock’s 50 day moving average price is $74.54 and its 200 day moving average price is $80.07.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The company had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. The business’s revenue for the quarter was down 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.22 earnings per share. Equities research analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

Several research analysts recently issued reports on GILD shares. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, October 3rd. Jefferies Group cut their target price on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating on the stock in a research report on Wednesday, August 31st. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday, September 26th. Piper Jaffray Cos. restated an “overweight” rating and set a $108.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, September 22nd. Ten investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $97.90.

In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at $9,115,028.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the completion of the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at $250,829,982.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment